Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Private placement

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Sep 16, 2020 2:24pm

137 Views

Post# 31568349

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Private placement

You're assuming an awful lot. The GVHD research had a lot of potential, there could have been many many different ways this could have played out..

The best option KLY could come up with was to "sell" back a more developed asset at the original price? Leaving itself with literally nothing but the potential to possibly acquire another company, with another phase 1 drug that needs developing and all its investors holding the bag?

On top of the fact that all the management seem to be connected with eachother, what are we supposed to think here?

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks